Companion Diagnostics Market Size, Share & Trends Analysis Report by Product & Service (Assay Kits & Reagents, Software & Services), by Technology (Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Others (e.g., gene chips, flow cytometry)), Indication, Cancer Type (within Oncology), Sample Type, Mode of Testing, End User and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035
|
Market Structure & Evolution |
|
|
Segmental Data Insights |
|
|
Demand Trends |
|
|
Competitive Landscape |
|
|
Strategic Development |
|
|
Future Outlook & Opportunities |
|
Companion Diagnostics Market Size, Share, and Growth
The global companion diagnostics market is experiencing robust growth, with its estimated value of USD 7 billion in the year 2025 and USD 18 billion by the period 2035, registering a CAGR of 9.9%. North America leads the market with market share of 48% with USD 3.4 billion revenue.
According to Dr Markus Müller, Head of Global Diagnostics at Roche Diagnostic, “With the launch of our advanced companion diagnostic assays, developed in partnership with global pharmaceutical leaders, we are driving precision oncology and enabling more effective targeted therapies worldwide.”
The worldwide companion diagnostics market is growing rapidly due to the increased acceptance of targeted therapies and personalized medicine, which increase patient outcomes. The rise of chronic diseases, like cancers, cardiovascular diseases, and autoimmune diseases, also drives demand for companion diagnostics, which provide direction for improved treatment based on genetic and molecular data.
North America is the most active region for companion diagnostics, with established healthcare services and institutional infrastructure, a well-established legal framework, and an early embrace of precision medicine. Investment in R&D and collaboration between drug companies and diagnostic companies is driving innovation in AI-based diagnostics and multiplex assays.
Furthermore, the market is expanding in the US and Europe without any government backing for the development of cancer care, not even in genomics. Emerging markets in the Asia-Pacific region are also growing quickly due to increasing awareness and access to health care.
Additionally global leaders, like Roche, Thermo Fisher Scientific, and Qiagen are widening their portfolios of state-of-the-art molecular diagnostic platforms, AI driven data analysis, and cloud-based solutions - align with new common growth trends of digitized, patient specific care that had led to changes in traditional processes like observed in smart logistics networks.
Companion Diagnostics Market Dynamics and Trends
Drivers: Surge in Personalized Medicine and Biomarker-Driven Targeted Therapies
- The growth of this market is intrinsically linked to the development of personalized medicine, which designs treatment according to the genetic and molecular profile of the affected patient. The increasing incidence of chronic and complex diseases such as cancers, cardiovascular diseases, autoimmune diseases have given rise to a dire demand for diagnostics to identify biomarkers that predict patient response to particular therapies.
- Further, Innovations in next-generation sequencing (NGS), liquid biopsy, and AI-based data analytics are making the diagnosis more accurate and enabling earlier and more efficient intervention strategies. The support offered from regulators and collaboration between the pharmaceutical companies and diagnostic developers further accelerate market expansion; this pushes building companion diagnostics as a common term of precision oncology and beyond.
Restraints: High Development Costs and Complex Regulatory Landscape Restrict Market Growth
- The companion diagnostic market is limited due to the challenges related to high development and validation costs of the diagnostic assay and the corresponding targeted therapy. Also, the regulatory pathway for approval is often cumbersome and lengthy because regulatory authorities require the diagnostic tests to be clinically validated - analytically and clinically - to show its safety and efficacy. This must be accomplished prior to release.
- This pursuant clinical validation adds to the time lag in the commercialization of companion diagnostics. Companion diagnostics, typically delivered through laboratory use, have the added burden of laboratory infrastructure and trained personnel, especially in resource-constrained healthcare systems, such as those in emerging markets. In addition to issues of availability, we also face the uncertainties of reimbursement for companion diagnostics and the challenges pending implementation within a fragmented healthcare system all significantly delayed the commercialization and availability of companion diagnostic testing in markets worldwide.
Opportunity: Rapid Infrastructure and Regulatory Expansion in Emerging Regions Creates Growth Avenues for Accessible and Affordable Companion Diagnostics
- With the rapid expansion of healthcare infrastructure in emerging markets such as India, China, Brazil and parts of Africa, accessible and affordable companion diagnostics have a significant opportunity. With rising rates of chronic diseases such as cancer in these regions, the need for personalized treatment - which companion diagnostics support - is also increasing.
- Regulatory bodies in these countries are also establishing clearer and faster approval pathways for their diagnostic tools making it easier for companies to enter the market. Additionally, there are growing rates of funding in their labs and hospitals, creating an even higher demand for affordable, region-specific diagnostic options that advance precision medicine.
Key Trend: Rise of AI‑Driven Biomarkers and Imaging Integration Enhances Precision and Streamlines Diagnostic Pathways
- The growing demand for precision medicine is changing the companion diagnostics market with the increased use of AI-based technologies that can analyze intricate, multivariate genomic, proteomic, and imaging data. AI is driving the rapid discovery of novel and more accurate biomarkers, and is integrating diagnostic imaging and molecular tests toward more rapid and targeted treatment decisions.
- Further, an illustration of AI advancements is discovering patterns in x-rays, CT and MRI scans or pathology images that would have simply been overlooked by humans, and these advances are already helping clinicians make better decisions about which patients are likely to do better with which treatments. More intelligent, integrated diagnostics are reduced time to treatment, improving clinical outcomes and scaling personalized medicine in both developed and developing healthcare system.
Companion Diagnostics Market Analysis and Segmental Data
Oncology Maintains Dominance in Global Market amid Expanding Use of Targeted Therapies and Growing Precision Medicine Adoption
- Oncology is the dominant segment in the international companion diagnostics market. This growth has been attributed to the increasing use of targeted therapies for cancer and to the focus on personalized medicine. The clinical need to identify mutations, such as EGFR, HER2 and BRCA, in selecting therapies for patients has made companion diagnostics vitally important for Cancer Company and patients.
- Additionally, the active development of drugs by pharmaceutical companies with an accompanying testing protocol means that it likely to continue to be key players in the companion diagnostics market. As new cancer biomarkers are identified and regulatory bodies align with the movements towards precision medicine, it is anticipated that oncology likely to remain entrenched in the companion diagnostics space in both established and emerging markets.
North America Dominates the Companion Diagnostics Market, Driven by Advanced Healthcare Infrastructure, Strong Pharmaceutical Collaborations, and Early Adoption of Precision Medicine
- North America is the largest region in the global market for companion diagnostics, supported by its remarkable healthcare infrastructure, investment in R&D, and collaboration between diagnostic companies and pharmaceutical companies. The region is also characterized by the implementation of precision medicine, thus allowing for regulatory environments to ease the approval and usage of companion diagnostic tests alongside targeted therapies at a rapid pace.
- Moreover, there is also widespread awareness and acceptance of precision medicine among both clinicians and patients of treatment alternatives, driving demand for companion diagnostics. Overall, North America is anticipated to maintain its dominant position within the market.
Companion Diagnostics Market Ecosystem
The companion diagnostics market is highly consolidated, with high concentration of main competitors. Tier 1 companies like Roche Diagnostics, Thermo Fisher Scientific, and Illumina dominate with advanced technology platforms and partnerships. Tier 2 companies like Qiagen, Agilent, and Guardant Health each occupy significant positions in the market. Tier 3 consists of small niche or new companies. Porter's Five Forces analysis showed moderate buyer concentration among pharmaceutical companies and health care providers and high supplier concentration as they are proprietary diagnostic technologies and are complicated.
Recent Development and Strategic Overview:
- In April 2025, Agilent Technologies demonstrated its most recent developments in companion diagnostics at the American Association for Cancer Research (AACR) Annual Meeting. Agilent released the Avida DNA Cancer Panels which allow for simultaneous DNA and methylation profiling from a single sample. The capability likely to facilitate further detection of genomic alterations from cancer-related DNA. Agilent also released the SureSelect Cancer Pan Heme Assay co-developed with Roswell Park Comprehensive Cancer Center for genomic profiling of hematologic malignancies.
In March 2025, Abbott Laboratories recently announced the expansion of its Alinity m molecular diagnostics platform to include a new series of assays intended for companion diagnostics development. These assays likely to enable identification of patients that may benefit from the use of targeted therapies in oncology. The new assays include improved sensitivity and a faster turnaround time for helping providers make important treatment decisions. Abbott recognizes the importance of expanding companion diagnostics as part of its continual efforts to advance personalized medicine and ultimately improve patient outcomes.
Report Scope
|
Attribute |
Detail |
|
Market Size in 2025 |
USD 7 Bn |
|
Market Forecast Value in 2035 |
USD 18 Bn |
|
Growth Rate (CAGR) |
9.9% |
|
Forecast Period |
2025 – 2035 |
|
Historical Data Available for |
2021 – 2024 |
|
Market Size Units |
USD Bn for Value
|
|
Report Format |
Electronic (PDF) + Excel |
|
Regions and Countries Covered |
|||||
|
North America |
Europe |
Asia Pacific |
Middle East |
Africa |
South America |
|
|
|
|
|
|
|
Companies Covered |
|||||
|
|
|
|
|
|
Companion Diagnostics Market Segmentation and Highlights
|
Segment |
Sub-segment |
|
By Product & Service |
|
|
By Technology |
|
|
By Indication |
|
|
By Cancer Type (within Oncology) |
|
|
By Sample Type |
|
|
By Mode of Testing |
|
|
By End User |
|
Frequently Asked Questions
The global companion diagnostics market was valued at USD 7 Bn in 2025.
The global companion diagnostics market industry is expected to grow at a CAGR of 9.9% from 2025 to 2035.
Rising demand for personalized medicine, targeted therapies, and advanced diagnostics is driving the growth of the companion diagnostics market.
In terms of companion diagnostics, the oncology segment accounted for the major share in 2025.
North America is a more attractive region for vendors.
Key players in the global companion diagnostics market include prominent companies such as Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, Inc., Almac Group, ArcherDX (a part of Invitae), bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Exact Sciences Corporation, Foundation Medicine, Inc., Guardant Health, Inc., Illumina, Inc., Invitae Corporation, Myriad Genetics, Inc., Qiagen N.V., Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., ThermoGenesis Holdings, Inc., and other key players along with several other key players.
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Companion Diagnostics Market Outlook
- 2.1.1. Global Companion Diagnostics Market Size (Value - USD Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2025-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global Companion Diagnostics Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Companion Diagnostics Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Source Roadmap and Developments
- 3.4. Trade Analysis
- 3.4.1. Import & Export Analysis, 2025
- 3.4.2. Top Importing Countries
- 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
- 3.5.1. Manufacturer
- 3.5.2. Supply Chain
- 3.5.3. End Consumer
- 3.6. Raw Material Analysis
- 3.1. Companion Diagnostics Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Surge in Personalized Medicine and Biomarker-Driven Targeted Therapies
- 4.1.2. Restraints
- 4.1.2.1. High Development Costs and Complex Regulatory Landscape Restrict Market Growth
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
- 4.4.1. Raw Components Sourcing
- 4.4.2. Manufacturing and Processing
- 4.4.3. Wholesalers/ E-commerce Platform
- 4.4.4. End-use/ Customers
- 4.5. Cost Structure Analysis
- 4.5.1. Parameter’s Share for Cost Associated
- 4.5.2. COGP vs COGS
- 4.5.3. Profit Margin Analysis
- 4.6. Pricing Analysis
- 4.6.1. Regional Pricing Analysis
- 4.6.2. Segmental Pricing Trends
- 4.6.3. Factors Influencing Pricing
- 4.7. Porter’s Five Forces Analysis
- 4.8. PESTEL Analysis
- 4.9. Global Companion Diagnostics Market Demand
- 4.9.1. Historical Market Size - Value (Value - USD Bn), 2021-2024
- 4.9.2. Current and Future Market Size - Value (Value - USD Bn), 2025–2035
- 4.9.2.1. Y-o-Y Growth Trends
- 4.9.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global Companion Diagnostics Market Analysis, by Product & Service
- 6.1. Key Segment Analysis
- 6.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Product & Service, 2021-2035
- 6.2.1. Assay Kits & Reagents
- 6.2.2. Software & Services
- 7. Global Companion Diagnostics Market Analysis, by Technology
- 7.1. Key Segment Analysis
- 7.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Technology, 2021-2035
- 7.2.1. Polymerase Chain Reaction (PCR)
- 7.2.2. In Situ Hybridization (ISH)
- 7.2.3. Immunohistochemistry (IHC)
- 7.2.4. Next-Generation Sequencing (NGS)
- 7.2.5. Others (e.g., gene chips, flow cytometry)
- 8. Global Companion Diagnostics Market Analysis, by Indication
- 8.1. Key Segment Analysis
- 8.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Indication, 2021-2035
- 8.2.1. Oncology
- 8.2.2. Neurology
- 8.2.3. Infectious Diseases
- 8.2.4. Cardiovascular Diseases
- 8.2.5. Others
- 9. Global Companion Diagnostics Market Analysis, by Cancer Type (within Oncology)
- 9.1. Key Segment Analysis
- 9.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Cancer Type (within Oncology), 2021-2035
- 9.2.1. Breast Cancer
- 9.2.2. Lung Cancer
- 9.2.3. Colorectal Cancer
- 9.2.4. Prostate Cancer
- 9.2.5. Other Cancer Types
- 10. Global Companion Diagnostics Market Analysis, by Sample Type
- 10.1. Key Segment Analysis
- 10.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Sample Type, 2021-2035
- 10.2.1. Blood
- 10.2.2. Tissue Biopsies
- 10.2.3. Saliva
- 10.2.4. Others
- 11. Global Companion Diagnostics Market Analysis, by Mode of Testing
- 11.1. Key Segment Analysis
- 11.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Mode of Testing, 2021-2035
- 11.2.1. Laboratory-Based
- 11.2.2. Point-of-Care
- 12. Global Companion Diagnostics Market Analysis, by End User
- 12.1. Key Segment Analysis
- 12.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by End User, 2021-2035
- 12.2.1. Pharmaceutical & Biopharmaceutical Companies
- 12.2.2. Reference Laboratories
- 12.2.3. Contract Research Organizations
- 12.2.4. Hospitals & Specialty Clinics
- 12.2.5. Others
- 13. Global Companion Diagnostics Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, by Region, 2021-2035
- 13.2.1. North America
- 13.2.2. Europe
- 13.2.3. Asia Pacific
- 13.2.4. Middle East
- 13.2.5. Africa
- 13.2.6. South America
- 14. North America Global Companion Diagnostics Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 14.3.1. Product & Service
- 14.3.2. Technology
- 14.3.3. Indication
- 14.3.4. Cancer Type
- 14.3.5. Sample Type
- 14.3.6. Mode of Testing
- 14.3.7. Mode of Operation
- 14.3.8. End User
- 14.3.9. Country
- 14.3.9.1. USA
- 14.3.9.2. Canada
- 14.3.9.3. Mexico
- 14.4. USA Global Companion Diagnostics Market
- 14.4.1. Country Segmental Analysis
- 14.4.2. Product & Service
- 14.4.3. Technology
- 14.4.4. Indication
- 14.4.5. Cancer Type
- 14.4.6. Sample Type
- 14.4.7. Mode of Testing
- 14.4.8. Mode of Operation
- 14.4.9. End User
- 14.5. Canada Global Companion Diagnostics Market
- 14.5.1. Country Segmental Analysis
- 14.5.2. Product & Service
- 14.5.3. Technology
- 14.5.4. Indication
- 14.5.5. Cancer Type
- 14.5.6. Sample Type
- 14.5.7. Mode of Testing
- 14.5.8. Mode of Operation
- 14.5.9. End User
- 14.6. Mexico Global Companion Diagnostics Market
- 14.6.1. Country Segmental Analysis
- 14.6.2. Product & Service
- 14.6.3. Technology
- 14.6.4. Indication
- 14.6.5. Cancer Type
- 14.6.6. Sample Type
- 14.6.7. Mode of Testing
- 14.6.8. Mode of Operation
- 14.6.9. End User
- 15. Europe Global Companion Diagnostics Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Product & Service
- 15.3.2. Technology
- 15.3.3. Indication
- 15.3.4. Cancer Type
- 15.3.5. Sample Type
- 15.3.6. Mode of Testing
- 15.3.7. Mode of Operation
- 15.3.8. End User
- 15.3.9. Country
- 15.3.9.1. Germany
- 15.3.9.2. United Kingdom
- 15.3.9.3. France
- 15.3.9.4. Italy
- 15.3.9.5. Spain
- 15.3.9.6. Netherlands
- 15.3.9.7. Nordic Countries
- 15.3.9.8. Poland
- 15.3.9.9. Russia & CIS
- 15.3.9.10. Rest of Europe
- 15.4. Germany Global Companion Diagnostics Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Product & Service
- 15.4.3. Technology
- 15.4.4. Indication
- 15.4.5. Cancer Type
- 15.4.6. Sample Type
- 15.4.7. Mode of Testing
- 15.4.8. Mode of Operation
- 15.4.9. End User
- 15.5. United Kingdom Global Companion Diagnostics Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Product & Service
- 15.5.3. Technology
- 15.5.4. Indication
- 15.5.5. Cancer Type
- 15.5.6. Sample Type
- 15.5.7. Mode of Testing
- 15.5.8. Mode of Operation
- 15.5.9. End User
- 15.6. France Global Companion Diagnostics Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Product & Service
- 15.6.3. Technology
- 15.6.4. Indication
- 15.6.5. Cancer Type
- 15.6.6. Sample Type
- 15.6.7. Mode of Testing
- 15.6.8. Mode of Operation
- 15.6.9. End User
- 15.7. Italy Global Companion Diagnostics Market
- 15.7.1. Country Segmental Analysis
- 15.7.2. Product & Service
- 15.7.3. Technology
- 15.7.4. Indication
- 15.7.5. Cancer Type
- 15.7.6. Sample Type
- 15.7.7. Mode of Testing
- 15.7.8. Mode of Operation
- 15.7.9. End User
- 15.8. Spain Global Companion Diagnostics Market
- 15.8.1. Country Segmental Analysis
- 15.8.2. Product & Service
- 15.8.3. Technology
- 15.8.4. Indication
- 15.8.5. Cancer Type
- 15.8.6. Sample Type
- 15.8.7. Mode of Testing
- 15.8.8. Mode of Operation
- 15.8.9. End User
- 15.9. Netherlands Global Companion Diagnostics Market
- 15.9.1. Country Segmental Analysis
- 15.9.2. Product & Service
- 15.9.3. Technology
- 15.9.4. Indication
- 15.9.5. Cancer Type
- 15.9.6. Sample Type
- 15.9.7. Mode of Testing
- 15.9.8. Mode of Operation
- 15.9.9. End User
- 15.10. Nordic Countries Global Companion Diagnostics Market
- 15.10.1. Country Segmental Analysis
- 15.10.2. Product & Service
- 15.10.3. Technology
- 15.10.4. Indication
- 15.10.5. Cancer Type
- 15.10.6. Sample Type
- 15.10.7. Mode of Testing
- 15.10.8. Mode of Operation
- 15.10.9. End User
- 15.11. Poland Global Companion Diagnostics Market
- 15.11.1. Country Segmental Analysis
- 15.11.2. Product & Service
- 15.11.3. Technology
- 15.11.4. Indication
- 15.11.5. Cancer Type
- 15.11.6. Sample Type
- 15.11.7. Mode of Testing
- 15.11.8. Mode of Operation
- 15.11.9. End User
- 15.12. Russia & CIS Global Companion Diagnostics Market
- 15.12.1. Country Segmental Analysis
- 15.12.2. Product & Service
- 15.12.3. Technology
- 15.12.4. Indication
- 15.12.5. Cancer Type
- 15.12.6. Sample Type
- 15.12.7. Mode of Testing
- 15.12.8. Mode of Operation
- 15.12.9. End User
- 15.13. Rest of Europe Global Companion Diagnostics Market
- 15.13.1. Country Segmental Analysis
- 15.13.2. Product & Service
- 15.13.3. Technology
- 15.13.4. Indication
- 15.13.5. Cancer Type
- 15.13.6. Sample Type
- 15.13.7. Mode of Testing
- 15.13.8. Mode of Operation
- 15.13.9. End User
- 16. Asia Pacific Global Companion Diagnostics Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. East Asia Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Product & Service
- 16.3.2. Technology
- 16.3.3. Indication
- 16.3.4. Cancer Type
- 16.3.5. Sample Type
- 16.3.6. Mode of Testing
- 16.3.7. Mode of Operation
- 16.3.8. End User
- 16.3.9. Country
- 16.3.9.1. China
- 16.3.9.2. India
- 16.3.9.3. Japan
- 16.3.9.4. South Korea
- 16.3.9.5. Australia and New Zealand
- 16.3.9.6. Indonesia
- 16.3.9.7. Malaysia
- 16.3.9.8. Thailand
- 16.3.9.9. Vietnam
- 16.3.9.10. Rest of Asia-Pacific
- 16.4. China Global Companion Diagnostics Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Product & Service
- 16.4.3. Technology
- 16.4.4. Indication
- 16.4.5. Cancer Type
- 16.4.6. Sample Type
- 16.4.7. Mode of Testing
- 16.4.8. Mode of Operation
- 16.4.9. End User
- 16.5. India Global Companion Diagnostics Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Product & Service
- 16.5.3. Technology
- 16.5.4. Indication
- 16.5.5. Cancer Type
- 16.5.6. Sample Type
- 16.5.7. Mode of Testing
- 16.5.8. Mode of Operation
- 16.5.9. End User
- 16.6. Japan Global Companion Diagnostics Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Product & Service
- 16.6.3. Technology
- 16.6.4. Indication
- 16.6.5. Cancer Type
- 16.6.6. Sample Type
- 16.6.7. Mode of Testing
- 16.6.8. Mode of Operation
- 16.6.9. End User
- 16.7. South Korea Global Companion Diagnostics Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Product & Service
- 16.7.3. Technology
- 16.7.4. Indication
- 16.7.5. Cancer Type
- 16.7.6. Sample Type
- 16.7.7. Mode of Testing
- 16.7.8. Mode of Operation
- 16.7.9. End User
- 16.8. Australia and New Zealand Global Companion Diagnostics Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Product & Service
- 16.8.3. Technology
- 16.8.4. Indication
- 16.8.5. Cancer Type
- 16.8.6. Sample Type
- 16.8.7. Mode of Testing
- 16.8.8. Mode of Operation
- 16.8.9. End User
- 16.9. Indonesia Global Companion Diagnostics Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Product & Service
- 16.9.3. Technology
- 16.9.4. Indication
- 16.9.5. Cancer Type
- 16.9.6. Sample Type
- 16.9.7. Mode of Testing
- 16.9.8. Mode of Operation
- 16.9.9. End User
- 16.10. Malaysia Global Companion Diagnostics Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Product & Service
- 16.10.3. Technology
- 16.10.4. Indication
- 16.10.5. Cancer Type
- 16.10.6. Sample Type
- 16.10.7. Mode of Testing
- 16.10.8. Mode of Operation
- 16.10.9. End User
- 16.11. Thailand Global Companion Diagnostics Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Product & Service
- 16.11.3. Technology
- 16.11.4. Indication
- 16.11.5. Cancer Type
- 16.11.6. Sample Type
- 16.11.7. Mode of Testing
- 16.11.8. Mode of Operation
- 16.11.9. End User
- 16.12. Vietnam Global Companion Diagnostics Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Product & Service
- 16.12.3. Technology
- 16.12.4. Indication
- 16.12.5. Cancer Type
- 16.12.6. Sample Type
- 16.12.7. Mode of Testing
- 16.12.8. Mode of Operation
- 16.12.9. End User
- 16.13. Rest of Asia Pacific Global Companion Diagnostics Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Product & Service
- 16.13.3. Technology
- 16.13.4. Indication
- 16.13.5. Cancer Type
- 16.13.6. Sample Type
- 16.13.7. Mode of Testing
- 16.13.8. Mode of Operation
- 16.13.9. End User
- 17. Middle East Global Companion Diagnostics Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Product & Service
- 17.3.2. Technology
- 17.3.3. Indication
- 17.3.4. Cancer Type
- 17.3.5. Sample Type
- 17.3.6. Mode of Testing
- 17.3.7. Mode of Operation
- 17.3.8. End User
- 17.3.9. Country
- 17.3.9.1. Turkey
- 17.3.9.2. UAE
- 17.3.9.3. Saudi Arabia
- 17.3.9.4. Israel
- 17.3.9.5. Rest of Middle East
- 17.4. Turkey Global Companion Diagnostics Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Product & Service
- 17.4.3. Technology
- 17.4.4. Indication
- 17.4.5. Cancer Type
- 17.4.6. Sample Type
- 17.4.7. Mode of Testing
- 17.4.8. Mode of Operation
- 17.4.9. End User
- 17.5. UAE Global Companion Diagnostics Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Product & Service
- 17.5.3. Technology
- 17.5.4. Indication
- 17.5.5. Cancer Type
- 17.5.6. Sample Type
- 17.5.7. Mode of Testing
- 17.5.8. Mode of Operation
- 17.5.9. End User
- 17.6. Saudi Arabia Global Companion Diagnostics Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Product & Service
- 17.6.3. Technology
- 17.6.4. Indication
- 17.6.5. Cancer Type
- 17.6.6. Sample Type
- 17.6.7. Mode of Testing
- 17.6.8. Mode of Operation
- 17.6.9. End User
- 17.7. Israel Global Companion Diagnostics Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Product & Service
- 17.7.3. Technology
- 17.7.4. Indication
- 17.7.5. Cancer Type
- 17.7.6. Sample Type
- 17.7.7. Mode of Testing
- 17.7.8. Mode of Operation
- 17.7.9. End User
- 17.8. Rest of Middle East Global Companion Diagnostics Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Product & Service
- 17.8.3. Technology
- 17.8.4. Indication
- 17.8.5. Cancer Type
- 17.8.6. Sample Type
- 17.8.7. Mode of Testing
- 17.8.8. Mode of Operation
- 17.8.9. End User
- 18. Africa Global Companion Diagnostics Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Product & Service
- 18.3.2. Technology
- 18.3.3. Indication
- 18.3.4. Cancer Type
- 18.3.5. Sample Type
- 18.3.6. Mode of Testing
- 18.3.7. Mode of Operation
- 18.3.8. End User
- 18.3.9. Country
- 18.3.9.1. South Africa
- 18.3.9.2. Egypt
- 18.3.9.3. Nigeria
- 18.3.9.4. Algeria
- 18.3.9.5. Rest of Africa
- 18.4. South Africa Global Companion Diagnostics Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Product & Service
- 18.4.3. Technology
- 18.4.4. Indication
- 18.4.5. Cancer Type
- 18.4.6. Sample Type
- 18.4.7. Mode of Testing
- 18.4.8. Mode of Operation
- 18.4.9. End User
- 18.5. Egypt Global Companion Diagnostics Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Product & Service
- 18.5.3. Technology
- 18.5.4. Indication
- 18.5.5. Cancer Type
- 18.5.6. Sample Type
- 18.5.7. Mode of Testing
- 18.5.8. Mode of Operation
- 18.5.9. End User
- 18.6. Nigeria Global Companion Diagnostics Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Product & Service
- 18.6.3. Technology
- 18.6.4. Indication
- 18.6.5. Cancer Type
- 18.6.6. Sample Type
- 18.6.7. Mode of Testing
- 18.6.8. Mode of Operation
- 18.6.9. End User
- 18.7. Algeria Global Companion Diagnostics Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Product & Service
- 18.7.3. Technology
- 18.7.4. Indication
- 18.7.5. Cancer Type
- 18.7.6. Sample Type
- 18.7.7. Mode of Testing
- 18.7.8. Mode of Operation
- 18.7.9. End User
- 18.8. Rest of Africa Global Companion Diagnostics Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Product & Service
- 18.8.3. Technology
- 18.8.4. Indication
- 18.8.5. Cancer Type
- 18.8.6. Sample Type
- 18.8.7. Mode of Testing
- 18.8.8. Mode of Operation
- 18.8.9. End User
- 19. South America Global Companion Diagnostics Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Central and South Africa Global Companion Diagnostics Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Product & Service
- 19.3.2. Technology
- 19.3.3. Indication
- 19.3.4. Cancer Type
- 19.3.5. Sample Type
- 19.3.6. Mode of Testing
- 19.3.7. Mode of Operation
- 19.3.8. End User
- 19.3.9. Country
- 19.3.9.1. Brazil
- 19.3.9.2. Argentina
- 19.3.9.3. Rest of South America
- 19.4. Brazil Global Companion Diagnostics Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Product & Service
- 19.4.3. Technology
- 19.4.4. Indication
- 19.4.5. Cancer Type
- 19.4.6. Sample Type
- 19.4.7. Mode of Testing
- 19.4.8. Mode of Operation
- 19.4.9. End User
- 19.5. Argentina Global Companion Diagnostics Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Product & Service
- 19.5.3. Technology
- 19.5.4. Indication
- 19.5.5. Cancer Type
- 19.5.6. Sample Type
- 19.5.7. Mode of Testing
- 19.5.8. Mode of Operation
- 19.5.9. End User
- 19.6. Rest of South America Global Companion Diagnostics Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Product & Service
- 19.6.3. Technology
- 19.6.4. Indication
- 19.6.5. Cancer Type
- 19.6.6. Sample Type
- 19.6.7. Mode of Testing
- 19.6.8. Mode of Operation
- 19.6.9. End User
- 20. Key Players/ Company Profile
- 20.1. Abbott Laboratories
- 20.1.1. Company Details/ Overview
- 20.1.2. Company Financials
- 20.1.3. Key Customers and Competitors
- 20.1.4. Business/ Industry Portfolio
- 20.1.5. Product Portfolio/ Specification Details
- 20.1.6. Pricing Data
- 20.1.7. Strategic Overview
- 20.1.8. Recent Developments
- 20.2. Adaptive Biotechnologies
- 20.3. Agilent Technologies, Inc.
- 20.4. Almac Group
- 20.5. ArcherDX (a part of Invitae)
- 20.6. bioMérieux SA
- 20.7. Bio-Rad Laboratories, Inc.
- 20.8. Danaher Corporation
- 20.9. Exact Sciences Corporation
- 20.10. Foundation Medicine, Inc.
- 20.11. Guardant Health, Inc.
- 20.12. Illumina, Inc.
- 20.13. Invitae Corporation
- 20.14. Myriad Genetics, Inc.
- 20.15. Qiagen N.V.
- 20.16. Roche Diagnostics
- 20.17. Siemens Healthineers
- 20.18. Sysmex Corporation
- 20.19. Thermo Fisher Scientific Inc.
- 20.20. ThermoGenesis Holdings, Inc.
- 20.21. Other key Players
- 20.1. Abbott Laboratories
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase and Others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players product portfolio
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources includes primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
